Amorolfine (loceryl) Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Amorolfine, is a morpholine antifungal drug that inhibits Δ14-sterol reductase and cholestenol Δ-isomerase, which depletes ergosterol and causes ignosterol to accumulate in the fungal cytoplasmic cell membranes. Marketed as Curanail, Loceryl, Locetar, and Odenil, amorolfine is commonly available in the form of a nail lacquer, containing 5% amorolfine hydrochloride as the active ingredient. It is used to treat onychomycosis. Amorolfine 5% nail lacquer in once-weekly or twice-weekly applications was shown in two decades-old studies to be between 60% and 71% effective in treating toenail onychomycosis; complete cure rates three months after stopping treatment were 38% and 46%. However, full experimental details of these trials were not available, and since they were first reported in 1992 there have been no subsequent trials.   Wikipedia

Chemistry

  • SMILES: CCC(C)(C)c1ccc(CC(C)CN2C[C@@H](C)O[C@@H](C)C2)cc1
  • InChIKey: MQHLMHIZUIDKOO-AYHJJNSGSA-N
  • Mol. Mass: 317.52
  • ALogP: 4.66
  • ChEMBL Molecule:
    amorolfine  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$28.3450 - $63.2335
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

allphar brand of amorolfine hydrochloride | amorolfine | amorolfine hcl | amorolfine hydrochloride | amorolfin hydrochloride | galderma brand of amorolfine hydrochloride | isdin brand of amorolfine hydrochloride | loceryl | locéryl | loceryl curanail | locetar | odenil | omicur | ro-144767000 | ro 14-4767-002 | ro-14-4767-002 | roche brand of amorolfine hydrochloride

Organizations (16)

Research & Development (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Mycoses

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Foot Dermatoses (Phase 4)

Onychomycosis (Phase 4)

Tinea Pedis ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial Organizations: 16

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue